Table 1.
Survey criteria | Questionnaire form for 1 year (0–12 M) | Questionnaire form for 2 years (12–24 M) |
---|---|---|
Patient background | ○ | – |
Primary disease | ○ | – |
Condition of administration | ○ | ○ |
Discontinuation/dropout | ○ | ○ |
Previous medication/treatment | ○ | – |
Concomitant drug/treatment | ○ | ○ |
Anti-JCV antibody | 0, 6, 12 M | 18, 24 M |
Anti-natalizumab antibody | ○ | ○ |
Anti-AQP4 antibody | ○ | ○ |
Clinical course | ○ | ○ |
Relapse | ○ | ○ |
EDSSa | 0, 3, 6, 9, 12 M | 15, 18, 21, 24 M |
Adverse event | ○ | ○ |
Laboratory testing | ○ | ○ |
M months, JCV John Cunningham virus, AQP4 aquaporin-4, EDSS expanded disability status scale
aSince EDSS was measured in a real-world clinical setting, the last evaluated score was used for analysis